Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times op-ed, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
Category: prescription drugs
The Biggest Health Care Reform in a Decade Could Lower Your Costs
Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times guest essay, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
The Biggest Health Care Reform in a Decade Could Lower Your Costs
Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times guest essay, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
What Are the Prescription Drug Provisions in the Inflation Reduction Act?
This slideshow explains the prescription drug provisions proposed in the Inflation Reduction Act as passed by the Senate
How much is health spending expected to grow?
This chart collection explores how health spending is expected to grow in coming years, based on National Health Expenditure projections from federal actuaries.
How much is health spending expected to grow?
This chart collection explores how health spending is expected to grow in coming years, based on National Health Expenditure projections from federal actuaries.
Everything You Need to Know About Paxlovid — Especially, Should You Take It?
Paxlovid has eclipsed other available therapies for preventing life-threatening covid symptoms in high-risk patients. But even as doctors praise its effectiveness, many say they have unanswered questions about prescribing the drug and want more and better data about it.
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
Seeking to Kick-Start Biden’s Agenda, Schumer Unveils a Bill for Medicare Drug Price Negotiations
In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.
